170991-34-1

Upstream product

• 4654-39-1 4-bromophenethanol 
• 100-39-0 benzyl bromide 

Downstream Products

• 666844-68-4 2-(2-(benzyloxy)ethyl)benzonitrile 
• 170991-45-4 4-(2-benzyloxyethyl)-phenyl boronic acid 
• 360775-78-6 2-[4-(2-benzoyloxyethyl)benzyl]phenol 
• 433331-71-6 4'-(2-Benzyloxyethyl)-2-(methoxymethyloxy)-4,6-dimethyldiphenylmethanol 
• 1580441-16-2 2-(4’-(2-(benzyloxy)ethyl)-[1,1’-biphenyl]-4-yl)-2-methylpropanoic acid 

Relevant academic research and scientific papers

Enhancing polo-like kinase 1 selectivity of polo-box domain-binding peptides

An important goal in the development of polo-like kinase 1 (Plk1) polo-box domain (PBD) binding inhibitors is selectivity for Plk1 relative to Plk2 and Plk3. In our current work we show that Plk1 PBD selectivity can be significantly enhanced by modulating

1-SUBSTITUTED-3- BETA-D-GLUCOPYRANOSYLATED NITROGENOUS HETERO- CYCLIC COMPOUNDS AND MEDICINES CONTAINING THE SAME

A compound having an SGLT1 and/or SGLT2 inhibitory activity which is usable as an agent for the prevention or treatment of diabetes, postprandial hyperglycemia, impaired glucose tolerance, diabetic complications, obesity, etc. It is a 1-substituted-3-(β-D

PYRAZOLE DERIVATIVES, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF, AND INTERMEDIATE FOR PRODUCTION THEREOF

The present invention provides pyrazole derivatives represented by the general formula: wherein R1 represents H, an optionally substituted C1-6 alkyl group etc.; one of Q and T represents a group represented by the general formula: or a group represented by the general formula: while the other represents an optionally substituted C1-6 alkyl group etc.; R2 represents H, a halogen atom, OH, an optionally substituted C1-6 alkyl group etc.; X represents a single bond, O or S; Y represents an optionally substituted C1-6 alkylene group etc.; Z represents -RB, -CORC etc. in which RB represents an optionally substituted C1-6 alkyl group etc.; and RC represents an optionally substituted C1-6 alkyl group etc.,; R4 represents H, an optionally substituted C1-6 alkyl group etc.; and R3, R5 and R6 represent H, a halogen atom etc., pharmaceutically acceptable salts thereof or prodrugs thereof, which exhibit an excellent inhibitory activity in human SGLT1 and are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, impaired glucose tolerance, impaired fasting glycemia, diabetic complications or obesity, and a disease associated with the increase of blood galactose level such as galactosemia, and pharmaceutical compositions comprising the same, pharmaceutical uses thereof, and intermediates for production thereof.

OXAZOLE DERIVATIVES AS INHIBITORS OF CYCLOOXYGENASE

A compound of the formula (I): wherein R1 is cycloalkyl, etc; R2 is (lower)alkoxy, etc; R3 is (lower)alkylene, etc; R4 is (lower)alkylene, etc; R5 is hydroxy, etc; X is "0", "S", "SO", or "S02"; Y is "CH" or "N"; n is 0 or 1; or pharmaceutically acceptable salts thereof, which are useful as a medicament

Inhibitor of cox

A compound of the formula (I): wherein R1 is cycloalkyl, etc; R2 is (lower)alkoxy, etc; R3 is (lower)alkylene, etc; R4 is (lower)alkylene, etc; R5 is hydroxy, etc; X is “O”, “S”, “SO”, or “SO2”; Y is “CH” or “N”; n is 0 or 1; or pharmaceutically acceptable salts thereof, which are useful as a medicament.

N-BENZODIOXOLYL, N-BENZODIOXANYL AND N-BENZODIOXEPINYL ARYLCARBONXAMIDE DERIVATIVES, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM

The present invention relates to a compound of the formula (I) : in which T, A, R, B Xi, Yi and n are as defined in Claim 1, and to the pharmaceutically usable derivatives, solvates and stereoisomers thereof, comprising a mixture thereof in all proportions, which can be used in the treatment of dyslipidaemia, and to pharmaceutical compositions comprising them.